STOCK TITAN
  1. Home
  2. Sec-filings
  3. URGN
  4. [Form 4] UroGen Pharma Ltd. Insider Trading Activity

UroGen Pharma (URGN) CMO sells 10,000 shares in Rule 10b5-1 trade

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of about $30.00 per share, with individual prices ranging from $30.00 to $30.05. After this sale, Schoenberg directly holds 134,985 Ordinary Shares. The transaction was executed pursuant to a pre-arranged trading plan adopted under Rule 10b5-1(c) on 08-15-2025, indicating it was scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider Schoenberg Mark
Role Chief Medical Officer
Sold 10,000 shs ($300K)
Type Security Shares Price Value
Sale Ordinary Shares 10,000 $30.00 $300K
Holdings After Transaction: Ordinary Shares — 134,985 shares (Direct, null)
Footnotes (1)
  1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 and $30.05. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Shares sold 10,000 shares Ordinary Shares sold on 2026-05-08 in open-market transaction
Weighted average sale price $30.00 per share Average across multiple trades between $30.00 and $30.05
Post-transaction holdings 134,985 shares Ordinary Shares directly owned after the reported sale
Price range $30.00–$30.05 Range of individual trade prices within the 10,000-share sale
Net shares sold 10,000 shares Net sell direction from transactionSummary
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Ordinary Shares financial
""security_title": "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schoenberg Mark
(Last)(First)(Middle)
400 ALEXANDER PARK DRIVE
(Street)
PRINCETON NEW JERSEY 08540
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares05/08/2026S(1)10,000D$30(2)134,985D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 and $30.05. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
/s/ Jason D. Smith, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did UroGen Pharma (URGN) report for Mark Schoenberg?

UroGen Pharma reported that Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares. The transaction was an open-market sale executed under a pre-arranged Rule 10b5-1(c) trading plan and left him with 134,985 Ordinary Shares directly owned after the sale.

At what price did UroGen Pharma (URGN) CMO Mark Schoenberg sell shares?

Mark Schoenberg’s 10,000-share sale used a weighted average price of about $30.00 per share. According to the disclosure, individual trades occurred in a narrow range between $30.00 and $30.05, reflecting multiple executions to complete the overall transaction.

How many UroGen Pharma (URGN) shares does Mark Schoenberg hold after this Form 4 sale?

Following the reported sale, Mark Schoenberg directly holds 134,985 Ordinary Shares of UroGen Pharma. This figure reflects his position after disposing of 10,000 shares in the open market and provides context for the relative size of the transaction.

Was the UroGen Pharma (URGN) insider sale by Mark Schoenberg under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made under a duly adopted Rule 10b5-1(c) trading plan. The plan’s adoption date is disclosed as 08-15-2025, indicating the sale was pre-scheduled rather than timed opportunistically by the insider.

What does the weighted average price disclosure mean in the UroGen Pharma (URGN) Form 4?

The weighted average price indicates the 10,000 shares were sold through multiple trades between $30.00 and $30.05. The company notes that detailed breakdowns of shares sold at each specific price are available to the issuer, shareholders, or SEC staff upon request.